Digital CMC beyond the ELN
Digital chemistry, manufacturing and controls (CMC) is not an ELN project: it is the work of keeping product and process knowledge connected as a product moves from pharmaceutical development through technology transfer, commercial manufacturing, quality oversight and post-approval change. Digital CMC Beyond the ELN is a white paper that sets out a connected-data blueprint for that continuity.
CMC knowledge often fragments across ELNs, LIMS platforms, instrument systems, statistical tools, manufacturing systems, quality applications, regulatory repositories and shared drives. Teams may have the evidence they need but still spend time reconstructing which formulation, material lot, method, process condition, specification or decision applies.
The blueprint explains how to link scientific rationale, material genealogy, analytical evidence, process parameters, quality events and approved commitments while each specialist system keeps its authoritative role. The goal is not one universal application. It is a governed information environment that makes product knowledge traceable, inspectable and usable across the lifecycle.
Why does digital CMC need more than an ELN?
Digital CMC needs more than an ELN because CMC decisions depend on information held in laboratory, manufacturing, quality, regulatory and enterprise systems, not only in experimental records. An electronic lab notebook supports experiment execution and scientific documentation, but on its own it cannot provide continuity across every stage.
A connected approach sets common identifiers, authoritative sources, version references and governed relationships. Teams can then move from development evidence to downstream product, process and quality decisions, and work backward from a decision through its analysis to the source records.
Who this white paper is for
This white paper is for CMC, process development, analytical, manufacturing, quality and regulatory leaders at pharmaceutical and biotech organizations who need product knowledge to hold up through technology transfer, investigations, validation and change.
For a one-page overview of how Uncountable approaches this, read the solution brief Pharmaceuticals: one platform for formulation and quality.
What's inside
Inside this white paper:
- Why digital CMC is a lifecycle continuity challenge, not simply an ELN implementation
- How knowledge management, quality risk management, data integrity and post-approval change shape the connected-data model
- The core relationships among products, materials, formulations, processes, analytical methods, results, quality attributes and decisions
- A five-layer reference architecture for capturing, governing, connecting, analyzing and acting on CMC evidence
- Six design principles, from governed identifiers to separating raw evidence, derived information and approved decisions
- How to preserve context across development, technology transfer, commercial manufacturing and continual improvement
- Risk-based approaches to assurance, validation, integrations, analytics and AI-enabled decision support
- An operating model for data ownership and stewardship, plus a phased roadmap and leadership checklist
Download the white paper to build a digital CMC foundation that cuts reconstruction work around transfer, investigation, validation and change, and keeps scientific understanding connected to the quality decisions that sustain product supply.
FAQs
Digital chemistry, manufacturing and controls (CMC) connects the scientific evidence, product definitions, process knowledge, analytical records, quality events and approved decisions needed across a pharmaceutical product's lifecycle. Digital CMC goes beyond electronic recordkeeping: it makes product and process knowledge traceable and usable as a product moves from development into technology transfer, commercial supply, monitoring and change.
Digital CMC Beyond the ELN is a white paper that covers why CMC is a lifecycle continuity challenge, the core data relationships, a five-layer reference architecture, six design principles, an operating model for data ownership and quality oversight, risk-based assurance and validation, and a phased implementation roadmap with a leadership checklist. It is written for pharmaceutical development, manufacturing, quality and regulatory leaders.
A connected CMC data model links products, presentations, strengths, markets, materials, suppliers, lots, formulations, process steps, samples, analytical methods, instruments, results, specifications, critical quality attributes, control strategies and quality events. It also keeps the experiments, protocols, reports, approvals and regulatory commitments behind each decision. The model does not need everything on day one, but critical objects should not become unlinked records.
Connected data improves pharmaceutical technology transfer by giving the receiving team a navigable path from each control to the evidence behind it. A document package may state a parameter range without linking to the studies, scale-up learning, risk assessments or exceptions that justify it. With connected data, receiving teams can trace critical parameters, methods, acceptance criteria and control strategies back to controlled evidence instead of the original scientist's memory.
In CMC, raw data, derived analysis and approved decisions should stay distinct but traceable. Raw instrument outputs are not the same as calculated results, models or summaries, and neither is the same as an approved release, risk assessment or regulatory position. Users need to know which layer they are viewing and be able to work backward from a decision through its analysis to the source records.
See the Platform Behind the Guide
